Escitalopram Tapering: Dose Equivalence and Microtaper Approaches

Escitalopram is one of the most frequently prescribed SSRIs in primary care and psychiatric practice, and its discontinuation profile is increasingly recognised as more problematic than its initial reputation suggested. The combination of a moderately long parent half-life, near-complete serotonin transporter (SERT) occupancy at standard doses, and the hyperbolic relationship between dose and receptor occupancy makes linear tapering schedules pharmacologically naive. This post summarises a clinician-facing protocol for stopping escitalopram with dose-equivalence tables, microtaper formulation options, and decision points for managing emergent symptoms.

Pharmacological basis for hyperbolic tapering

Escitalopram is the S-enantiomer of citalopram and is metabolised primarily by CYP2C19, with secondary contributions from CYP3A4 and CYP2D6. The parent compound has an elimination half-life of approximately 27–32 hours; its principal metabolite, S-desmethylcitalopram (S-DCT), contributes minimally to clinical effect. Steady-state plasma concentrations are achieved within 7–10 days. Once-daily dosing is supported by the half-life, but the pharmacokinetic profile is not the limiting factor for taper design — receptor occupancy is.

PET imaging studies (Meyer et al., 2004; Sørensen et al., 2013) demonstrate that SERT occupancy follows a hyperbolic curve. At 10 mg of escitalopram, SERT occupancy is approximately 80%. At 5 mg, occupancy remains around 65–70%. Even at 1 mg, occupancy is still in the range of 40–50%. Functionally, this means halving a 10 mg dose to 5 mg removes only a small fraction of pharmacological effect, whereas halving 2 mg to 1 mg removes substantially more. The Maudsley Deprescribing Guidelines (Horowitz & Taylor, 2024) and the 2023 Lancet Psychiatry review by Horowitz et al. argue that linear taper schedules (e.g., 20 → 15 → 10 → 5 → 0 mg) front-load the easy reductions and concentrate the largest functional decrements at the end of the taper, which is precisely where most discontinuation reactions occur.

Hyperbolic tapering reverses this. Reductions are calculated as a percentage of the current dose, not the starting dose, and reductions in absolute milligram terms become progressively smaller as the dose decreases. The pharmacological target is approximately equal decrements in SERT occupancy at each step — typically 5–10 percentage points of occupancy per reduction in stable patients, and as little as 2–4 percentage points in patients with prior failed taper attempts.

Dose-occupancy reference table

The following approximate values can be used at the point of care. They are derived from the curves published by Sørensen et al. (2013) and reproduced in the Maudsley Deprescribing Guidelines.

| Escitalopram dose | Approx. SERT occupancy | | | | 20 mg | ~85% | | 15 mg | ~83% | | 10 mg | ~80% | | 5 mg | ~68% | | 4 mg | ~64% | | 3 mg | ~58% | | 2 mg | ~50% | | 1 mg | ~42% | | 0.5 mg | ~30% | | 0.25 mg | ~20% | | 0.1 mg | ~10% |

Note the steep change in occupancy between 1 mg and 0.25 mg — a fivefold dose reduction that corresponds to a roughly 20-percentage-point drop in occupancy. This is why the final 1–2 mg of escitalopram is, for many patients, the hardest portion of the taper, and why it cannot be skipped or accomplished by simply "stopping at the lowest licensed tablet."

Suggested taper schedule

The reduction interval should be at least one half-life equilibration period — for escitalopram, a minimum of 2–4 weeks between reductions in patients without prior withdrawal history. Patients with a history of failed taper, long duration of treatment (>2 years), or prior antidepressant withdrawal should taper at 4-week intervals or longer, with smaller step sizes.

A representative hyperbolic schedule for a patient starting at 20 mg, using approximately 10% occupancy reductions:

Step	Dose	Approx. reduction in occupancy
Baseline	20 mg	—
1	10 mg	~5 pp
2	5 mg	~12 pp
3	3 mg	~10 pp
4	2 mg	~8 pp
5	1.3 mg	~6 pp
6	0.8 mg	~6 pp
7	0.5 mg	~5 pp
8	0.3 mg	~5 pp
9	0.15 mg	~5 pp
10	0.05 mg	~3 pp
11	0 mg	—

This is a representative schedule, not a prescription. Step sizes are adjusted by the clinician according to symptom emergence between steps — if discontinuation symptoms occur, the previous step is reinstated until stable, then a smaller decrement is attempted. Patients who reach 5 mg without incident may not need every intermediate step below; the schedule reflects the worst-case curve, not the typical patient.

Formulations and how to dose below 5 mg

Escitalopram is licensed in the UK and US as 5 mg, 10 mg, and 20 mg film-coated tablets and as a 5 mg/5 mL oral solution. The oral solution is the cleanest tool for sub-tablet dosing, because it permits volumetric titration to any value the prescriber chooses. Dosing below 1 mg with the oral solution requires a 1 mL oral syringe with 0.1 mL graduations (1 mg per 1 mL).

Alternatives when the oral solution is not available or not tolerated:

• Compounded liquid. Specialty compounding pharmacies will prepare an escitalopram suspension at clinician-specified concentrations (e.g., 1 mg/mL or 0.1 mg/mL). This is helpful for the bottom end of the curve where measurement accuracy matters most. Stability data should be requested from the compounder; expiry is typically 14–28 days.
• Tapering strips. In Europe, packaged daily-dose strips are available from compounding pharmacies (e.g., the Cinderella Therapeutics model used by Groot & van Os, 2018) at decrementing doses. These are practical for patients but expensive and not reimbursed in most jurisdictions.
• Tablet splitting. A 10 mg tablet can be quartered with a pill cutter to approximate 2.5 mg, but accuracy below this is poor. Splitting is not recommended for the final 0.5–2 mg portion of the taper.
• Bead counting. Escitalopram is not a beaded capsule formulation, so the bead-counting approach used for venlafaxine XR or duloxetine does not apply.

The 5 mg tablet is not scored in most jurisdictions and should not be relied upon for precise sub-5 mg dosing.

Differential diagnosis of emergent symptoms

When a patient becomes symptomatic during or after a taper step, the prescriber must distinguish three possibilities: discontinuation syndrome, relapse of the primary mood or anxiety disorder, and emergence of a new condition.

Discontinuation syndrome typically appears within 1–7 days of a dose reduction, plateaus within 1–2 weeks, and resolves either with time (4–6 weeks in most cases) or with reinstatement of the prior dose (usually within 24–72 hours). The DESS (Discontinuation-Emergent Signs and Symptoms) scale is a useful structured assessment. Classic symptoms include dizziness, "brain zaps" or electric-shock paraesthesias, nausea, insomnia with vivid dreaming, irritability, flu-like fatigue, and sensory hypersensitivity. Escitalopram has a lower incidence of these phenomena than paroxetine or venlafaxine but a higher incidence than fluoxetine.

Relapse has a longer latency from dose change (typically >3 weeks), is symptomatically congruent with the patient's index presentation, and does not respond rapidly to dose reinstatement. A useful clinical rule is the "two-week test" — if symptoms appear within 14 days of a reduction and resolve within 72 hours of reinstating the prior dose, discontinuation is the more likely explanation.

Emergent disorder (e.g., a new anxiety disorder, an unrelated medical condition presenting with similar symptoms, hyperthyroidism, vestibular pathology) should always be considered when the temporal pattern does not fit either discontinuation or relapse. Dizziness and palpitations during taper, in particular, warrant orthostatic vitals and basic labs before assuming withdrawal.

Specific scenarios

Long-term users (>2 years)

Receptor adaptation accumulates with duration of exposure. For patients on escitalopram for more than 2 years, the Maudsley Deprescribing Guidelines recommend the slowest reduction increments (approximately 5% occupancy per step, often translating to 6–12 months of total taper time once doses fall below 5 mg). Counsel patients in advance that the bottom of the curve may take longer than the top.

Pregnancy and perinatal tapering

A clinician contemplating taper during pregnancy must weigh withdrawal reactions in the patient against neonatal adaptation syndrome at the time of delivery. ACOG and NICE both advise individualised decisions; abrupt discontinuation in pregnancy is generally not advised in patients with significant prior depressive episodes. If taper is undertaken, the same hyperbolic principles apply, with attention to changes in CYP2C19 activity across trimesters.

CYP2C19 genotype

Poor metabolisers (CYP2C19 *2/*2 or *2/*3) have higher escitalopram exposure at any given dose and may experience more pronounced symptoms during early taper steps despite the small reduction in occupancy. Ultra-rapid metabolisers (CYP2C19 *17/*17) may, paradoxically, find discontinuation easier in the upper dose range but no easier at the bottom of the curve, since occupancy at sub-mg doses is determined more by dose than by clearance. Pharmacogenomic testing is not required to taper, but should be considered when discontinuation has previously been intolerable.

Switching to fluoxetine for taper completion

For patients unable to obtain a liquid or compounded formulation, a fluoxetine bridge is sometimes proposed (typically 10–20 mg fluoxetine substituted for 10–20 mg escitalopram, then tapering fluoxetine over weeks). The evidence base is weaker than commonly assumed: the long half-life of fluoxetine (and norfluoxetine, ~7–15 days) does not produce a smooth auto-taper at the bottom of its occupancy curve, where the same hyperbolic steepness applies. The bridge is a pragmatic option when no liquid is available, but it is not a substitute for hyperbolic dosing.

Reinstatement

When a patient develops significant discontinuation symptoms, the standard response is to reinstate the previous tolerated dose, hold for at least 2–4 weeks until baseline is restored, and then resume taper with a smaller decrement (commonly half the previous step size). Reinstatement is most reliable when initiated within 6–12 weeks of dose change; delayed reinstatement (months later) is less consistently effective and may require more careful titration upward. If reinstatement fails, consider whether sensitisation has occurred and consult deprescribing-specialist guidance (e.g., the Maudsley protocol for protracted withdrawal).

Clinical pearls

• Calculate reductions as a percentage of the current dose, not the starting dose. A 10% reduction from 20 mg is 2 mg; a 10% reduction from 2 mg is 0.2 mg.
• Plan from the bottom up. Decide in advance how the patient will dose 1 mg, 0.5 mg, and 0.1 mg before initiating the first reduction. The oral solution (5 mg/5 mL) plus a 1 mL graduated syringe is the simplest tool.
• Use a 2–4 week minimum interval between reductions; extend to 4–8 weeks for long-term users or anyone with prior withdrawal history.
• The "two-week test" distinguishes discontinuation from relapse: symptoms within 14 days of a reduction that resolve within 72 hours of reinstatement are almost always discontinuation.
• Avoid bridging to fluoxetine as a default. It is a fallback when liquid escitalopram is unavailable, not a shortcut around hyperbolic tapering.
• Document the curve and the schedule in the chart, and give the patient a written copy with the specific volumes or strengths they will measure at each step. Verbal-only instructions are a frequent source of dosing error at the bottom of the curve.

Selected references

• Horowitz MA, Taylor D. The Maudsley Deprescribing Guidelines: Antidepressants, Benzodiazepines, Gabapentinoids and Z-Drugs. Wiley, 2024.
• Horowitz MA, Framer A, Hengartner MP, Sørensen A, Taylor D. Estimating risk of antidepressant withdrawal from a review of published data. CNS Drugs 2023.
• Sørensen A, Ruhé HG, Munkholm K. The relationship between dose and serotonin transporter occupancy of antidepressants — a systematic review. Molecular Psychiatry 2022.
• Meyer JH, Wilson AA, Sagrati S, et al. Serotonin transporter occupancy of five SSRIs at different doses: a PET study. Am J Psychiatry 2004;161:826–835.
• Groot PC, van Os J. Antidepressant tapering strips to help people come off medication more safely. Psychosis 2018;10:142–145.
• NICE NG215. Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management, 2022.

---

For more clinician resources on safe deprescribing and tapering, visit tapermeds.com.